Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

Abstract

Cancer Research UK.

Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer

“…The reasons for this difference could be that trstuzumab is a MoAb specially targeting HER2 and all patients in anti-HER2 subgroup are diagnosed HER2 positive. The decreasing OS in anti-EGFR subgroup may due to the limited clinical trials in gastric and gastroesophageal cancer and in fact some trials in other cancers draw the similar conclusions (Douillard et al, 2010b;Crosby et al, 2013). The PFS was significantly improved in the anti-HER2 subgroup (HR 0.72, 95% CI 0.60-0.84, P<0.05; I 2 =0.0%, p =0.897), but was significantly reduced in anti-EGFR subgroup (HR 1.13, 95% CI 0.98 -1.28, P<0.05).…”

Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma

“…Similarly, SCOPE1 trials in patients in the UK did not show any benefits to adding cetuximab to a standard chemo-/radiotherapy treatment regimen. However, in a multi- center phase II trial in Chinese patients with non-resectable, locally advanced ESCC, it was found that cetuximab can be safely used concurrently with chemo-and radiotherapy and may actually increase the clinical response rate (18,19). The reasons for these conflicting results of cetuximab combination therapy remain unclear, but recent data point to the influence of mutations in, or amplification of, specific genes; for instance, combination therapy had different survival outcomes for patients depending on the presence of EGFR or MET gene amplifications, or mutations in EGFR, KRAS, or PI3CA (20,21).…”

Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer

“…This may be the result of a low expression of EGFR and mutation of the K-RAS gene of the tumors investigated in this study (26). Currently it is not clear whether addition of cetuximab to the radio-chemotherapy of esophageal cancer can improve the overall survival of these patients (27,28). In the SCOPE1 trial, treatment included two courses of induction chemotherapy with cisplatin (60 mg/m 2 on day 1) and capecitabine (625 mg/m 2 twice daily on days 1-21) followed by radio-chemotherapy with 50 Gy of radiotherapy plus two concurrent courses of chemotherapy with or without the addition of cetuximab.…”